Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

Publisher： Karger

E-ISSN： 1421-9913|59|3-4|131-135

ISSN： 0014-3022

Source： European Neurology, Vol.59, Iss.3-4, 2007-11, pp. : 131-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?

By  

Neuroepidemiology, Vol. 21, Iss. 6, 2002-11 ,pp. : 310-

Karger

Access to resources Recommend Favorite

Azathioprine and Interferon β1a in Relapsing-Remitting Multiple Sclerosis Patients: Increasing Efficacy of Combined Treatment

By  

European Neurology, Vol. 51, Iss. 1, 2004-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients

By  

European Neurology, Vol. 61, Iss. 3, 2009-01 ,pp. : 177-182

Karger

Access to resources Recommend Favorite

CXCL11 (Interferon-Inducible T-Cell Alpha Chemoattractant) and Interleukin-18 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Methylprednisolone

By  

European Neurology, Vol. 58, Iss. 4, 2007-09 ,pp. : 228-232

Karger

Access to resources Recommend Favorite

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait

By  

Medical Principles and Practice, Vol. 22, Iss. 5, 2013-06 ,pp. : 495-499

Karger

Access to resources Recommend Favorite